Features

Top 25 Pharma and Biopharma Report

Based on 2015 Sales, in $U.S. Million

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma


1. Novartis $49,414
2. Pfizer $48,851
3. Sanofi $40,486
4. Merck & Co. $39,498
5. Roche $37,667
6. GlaxoSmithKline $35,463
7. Gilead $32,639
8. Johnson & Johnson $31,430
9. AstraZeneca $24,708
10. AbbVie $22,859
11. Amgen $21,662
12. Eli Lilly & Co. $19,958
13. Teva $19,652
14. Bristol-Myers Squibb $16,560
15. Boehringer Ingelheim $16,167
16. Takeda $16,068
17. Novo Nordisk $15,801
18. Allergan $15,071
19. Bayer $15,017
20. Merck KGaA $14,034
21. Otsuka $11,993
22. Biogen $10,764
23. Mylan $9,363
24. Celgene $9,256
25. Daiichi Sankyo $8,770


Contributors

Editor: Tim Wright
Associate Editor: Kristin Brooks

All profiles compiled by Tim Wright, except Gilead, Amgen, Boehringer-Ingelhaim and Biogen, by Kristin Brooks Pipeline/revenue information compiled by Kristin Brooks


*Profile information is sourced from each company’s annual report along with press releases distributed throughout the year.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters